PROVECTUS BIOPHARMACEUTICALS I (PVCT) Stock Price, Forecast & Analysis

USA • NYSE Arca • NYSEARCA:PVCT • US74373P1084

0.05
-0.02 (-28.57%)
Last: Oct 13, 2016, 08:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

PVCT Key Statistics, Chart & Performance

Key Statistics
Market Cap18.52M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares370.36M
Float355.55M
52 Week High0.55
52 Week Low0.05
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-0.05
PEN/A
Fwd PEN/A
Earnings (Next)04-12
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
PVCT short term performance overview.The bars show the price performance of PVCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

PVCT long term performance overview.The bars show the price performance of PVCT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PVCT is 0.05 null. In the past month the price decreased by -50%. In the past year, price decreased by -90.91%.

PROVECTUS BIOPHARMACEUTICALS I / PVCT Daily stock chart

PVCT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
PVCT Full Technical Analysis Report

PVCT Financial Highlights

Over the last trailing twelve months PVCT reported a non-GAAP Earnings per Share(EPS) of -0.05.


Industry RankSector Rank
PM (TTM) 100.15%
ROA -257.04%
ROE -478.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
PVCT financials

PVCT Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
PVCT Analyst EstimatesPVCT Analyst Ratings

PVCT Ownership

Ownership
Inst Owners0.06%
Ins Owners8.24%
Short Float %0.23%
Short Ratio0.24
PVCT Ownership

About PVCT

Company Profile

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Company Info

PROVECTUS BIOPHARMACEUTICALS I

7327 OAK RIDGE HIGHWAY SUITE A

KNOXVILLE TN 37931

CEO: Alfred E. Smith IV

Phone: 866-594-5999

PROVECTUS BIOPHARMACEUTICALS I / PVCT FAQ

What does PVCT do?

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.


What is the current price of PVCT stock?

The current stock price of PVCT is 0.05 null. The price decreased by -28.57% in the last trading session.


Does PROVECTUS BIOPHARMACEUTICALS I pay dividends?

PVCT does not pay a dividend.


How is the ChartMill rating for PROVECTUS BIOPHARMACEUTICALS I?

PVCT has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.


Should I buy PVCT stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PVCT.


What is the outstanding short interest for PROVECTUS BIOPHARMACEUTICALS I?

The outstanding short interest for PROVECTUS BIOPHARMACEUTICALS I (PVCT) is 0.23% of its float.